Quick Answer
bioAffinity Technologies, Inc. reported Operating Income Loss of -$10.57 million for the year ending 2025.
- bioAffinity Technologies, Inc. showed a decrease of -18.1% in Operating Income Loss from 2024 to 2025.
- This data is from bioAffinity Technologies, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2021: -$526.3 thousand | Q1 2022: -$727.0 thousand | Q2 2022: -$684.1 thousand | Q3 2022: -$976.2 thousand | Q1 2023: -$1.56 million | Q2 2023: -$1.78 million | Q3 2023: -$2.29 million | Q1 2024: -$1.95 million | Q2 2024: -$2.09 million | Q3 2024: -$1.97 million | Q1 2025: -$2.63 million | Q2 2025: -$2.52 million | Q3 2025: -$2.29 million.
- Over the full 5 years of available data (2021 to 2025), bioAffinity Technologies, Inc.'s Operating Income Loss has declined by 379.1%.
- Historical annual values: Fiscal year 2025: -$10.57 million | Fiscal year 2024: -$8.95 million | Fiscal year 2023: -$7.97 million | Fiscal year 2022: -$4.01 million | Fiscal year 2021: -$2.21 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: